Skip to main content

Table 3 Patients with IT or TT at or after GKRS1

From: Concomitant radiosurgical and targeted oncological treatment improves the outcome of patients with brain metastases from gastrointestinal cancer

IT or TT at or after GKRS1 “IT or TT Group” (n = 21)

Number of Patients (%)

Bevacizumab ¹

10 (47%)

Cetuximab ²

4 (19%)

Panitumumab ²

2 (9%)

Sunitinib ³

1 (5%)

Nivolumab4

1 (5%)

Trastuzumab5

1 (5%)

Regorafenib6 + Bevacizumab ¹

1 (5%)

Panitumumab ² + Bevacizumab ¹

1 (5%)

  1. ¹ VEGF-A vascular endothelial growth factor A inhibitor, ² EGFR epidermal growth factor receptor inhibitor, ³ RTK receptor tyrosine kinase inhibitor, 4PD-1 programmed cell death-1 inhibitor, 5HER2 human epidermal growth factor receptor 2, 6RTK receptor tyrosine kinase inhibitor
  2. GKRS1 first Gamma Knife radiosurgery, IT immunotherapy, TT targeted therapy
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us